Overview

Diana is a rockstar and a brilliant lawyer. Her level of client service is outstanding. - Chambers USA

Diana Watral is a Chambers-ranked litigation partner and trial lawyer who represents companies in complex commercial and bet-the-company litigation. She focuses on high-stakes matters for some of the world’s largest pharmaceutical and life sciences companies, with an emphasis on multidistrict litigation, products liability, False Claims Act, contract disputes and class actions.

Diana currently leads three major multidistrict litigations for Eli Lilly and Company related to insulin pricing and GLP-1 products liability claims, as well as Lilly’s nationwide litigation against sellers of knock-off GLP-1 weight loss medicines. She recently led Lilly’s successful defense against a preliminary injunction brought by its biggest competitor, Novo Nordisk, concerning GLP-1 medicines—a win that earned Diana Litigator of the Week. She also represents Lilly in numerous other significant matters in state and federal courts throughout the country.

Diana is an experienced trial lawyer. She led Lilly’s defense in a $1.25 billion breach-of-contract jury trial; served as lead trial counsel to Flexus Biosciences, a Bristol-Myers Squibb subsidiary, in a $1 billion trade secret jury trial; defended Abbott in a $1 billion False Claims Act jury trial; and defended Baxter Healthcare in a $400 million contract trial and multiple products liability trials. She also led the defense of a large pharmaceutical company in an arbitration in which a competitor sought to invalidate a patent-royalty agreement and led the defense of a breach-of-contract arbitration for a large oil company.

Diana led Allergan (AbbVie) to defeat a massive False Claims Act case at summary judgment, where the relator alleged a nationwide, 15-year scheme to defraud the government through kickbacks and off-label promotion. She also obtained dismissal of an antitrust case asserting that AbbVie created a “patent thicket” for Humira, the highest-selling drug in history and dismissal of False Claims Act retaliation claims brought against AbbVie by several former employees following an Office of Ethics and Compliance investigation.

Chambers USA has described Diana as “whip smart,” “a rockstar” and “a brilliant lawyer.” Legal 500 United States has recognized her for Healthcare: Life Sciences, calling her “brilliant, creative and tenacious,” and named her a “Next Generation Partner” in Commercial Disputes. Crain’s recognized Diana as a “Notable Litigator and Trial Attorney,” and she was named one of four Law360 “Rising Stars” for her trial work. She was also profiled by Bloomberg Law in its “They’ve Got Next” series for Healthcare and Life Sciences and is named on the Benchmark Litigation “40 & Under Hot List” for her products liability, commercial litigation and False Claims Act work. Diana has been profiled twice as Litigator of the Week for her work for Lilly and Bristol-Myers Squibb.

More

Recognition

Recognized by Chambers USA for Litigation: General Commercial – Up and Coming

Recommended as a “Next Generation Partner” in General Commercial Disputes by Legal 500

Recognized by Crain’s as a “Notable Litigator and Trial Attorney”

Profiled by Bloomberg Law, “They’ve Got Next: Healthcare and Life Sciences Fresh Face Diana Watral,” April 22, 2021

Named in Benchmark Litigation’s “40 & Under Hot List”

Recognized by Benchmark Litigation for products liability, commercial litigation and False Claims Act work 

Profiled by Law360 as a “Rising Star” for trial work

Named “Litigator of the Week” by the American Lawyer

Credentials

Admissions & Qualifications

  • Illinois

Education

  • University of Chicago Law SchoolJ.D.with Highest Honors2010

    Graduated first in class

    Order of the Coif

    Kirkland & Ellis Scholar

    Executive Editor, The University of Chicago Law Review

  • Georgetown UniversityB.A., Governmentmagna cum laude, with Honors, with Distinction2007